Description |
Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, reduces several effects of tetrahydrocannabinol (THC).
|
Target |
CB1 Receptor
Human Endogenous Metabolite
|
In Vitro |
The effect of THC is significantly attenuated when slices are pre-treated with Pregnenolone 100 nM (15.1±1.8 % of inhibition). These effects are likely due to a pre-synaptic action of Pregnenolone. Thus, Pregnenolone blocks the increase in paired-pulse ratio (PPR) induced by THC but does not modify either the amplitude or the decay time of miniature EPSC (mEPSC)[1].
|
In Vivo |
Pregnenolone administration (2-6 mg/kg) blocks THC-induced food-intake in Wistar rats and in C57BL/6N mice, and blunts the memory impairment induced by THC in mice, but it does not modify these behaviors per se. Injections of Pregnenolone (2 and 4mg/kg) before each self-administration session reduce the intake of WIN 55,212-2 and reduce the break-point in a progressive ratio schedule[1].
|
Animal Admin |
Mice and Rats[1] Adult male Wistar rats (weighing 320-340g), Sprague Dawley male rats (weighing 330-350g), C57BL/6N mice (2-3 months) and CD1 mice (weighing 25-30 g at the beginning of the experiments) are used. Pregnenolone is injected subcutaneously (sc). The injection volumes are 1 mL/kg of body weight for rats and 10 mL/kg for mice[1].
|
Density | 1.1±0.1 g/cm3 |
Boiling Point | 443.3±45.0 °C at 760 mmHg |
Flash Point | 188.9±21.3 °C |
Exact Mass | 316.240234 |
PSA | 37.30000 |
LogP | 4.52 |
Vapour Pressure | 0.0±2.4 mmHg at 25°C |
Storage condition | 2~8℃ |